Europe’s Quest for Health Sovereignty: Building the Next Generation of Biotechnology

Editorial — Europe’s Quest for Health Sovereignty: Building the Next Generation of Biotechnology

Europe is entering a decisive decade. Health has become far more than a public policy: it is now a strategic asset at the crossroads of competitiveness, industrial resilience, technological leadership and geopolitical security.

The race for biotechnology is no longer simply a race for medical innovation. It is increasingly a race for industrial leadership, economic sovereignty and global influence. The countries that succeed in mastering biotechnology will not only shape the future of healthcare but also secure leadership in advanced manufacturing, artificial intelligence, data-driven medicine and the wider bioeconomy.

As global competition accelerates, the United States and China are investing massively across the entire biotechnology value chain—from fundamental research and clinical development to industrial manufacturing and commercial deployment. Europe, meanwhile, continues to produce world-class science, yet too often fails to transform scientific excellence into industrial leadership. Bridging this gap has become one of the European Union’s defining economic and strategic challenges.

This new reality is reshaping the European agenda.

Across the European institutions, a broad consensus is emerging that biotechnology will become one of the key drivers of Europe’s future prosperity. It will not only determine the evolution of healthcare but will also strengthen Europe’s competitiveness across strategic sectors, reinforce supply-chain resilience and contribute to Europe’s long-term technological sovereignty.

It is within this context that the forthcoming Biotech Act II takes on its full significance.

More than another legislative initiative, it offers a unique opportunity to rethink Europe’s entire biotechnology ecosystem. Its ambition must go beyond supporting research and innovation. It must create the conditions for innovative companies to grow, manufacture, scale and remain in Europe. Too often, discoveries made in European laboratories generate investment, production and high-value jobs elsewhere. Reversing this trend will be essential if Europe is to compete successfully in the decades ahead.

The contributions gathered in this special edition illustrate both the scale of this opportunity and the complexity of the challenge. They demonstrate that Europe already possesses exceptional scientific talent, leading universities, innovative companies and world-class healthcare systems. What remains fragmented are the connections between research, investment, regulation, manufacturing and market deployment.

Building these bridges will require more than a single legislative proposal.

Alongside the Critical Medicines Act, the Pharmaceutical Package and the European Life Sciences Strategy, the Biotech Act II should become one of the foundations of a genuine European biotechnology strategy—one capable of accelerating clinical research, mobilising investment, simplifying regulatory pathways, strengthening manufacturing capacity and enabling European companies to scale successfully within the Single Market.

Competitiveness, however, cannot become an objective in itself. Europe’s strength has always been its ability to combine innovation with solidarity, scientific excellence with public trust, and industrial ambition with equitable access to healthcare. Strengthening Europe’s biotechnology sector must therefore go hand in hand with faster patient access to innovation, resilient supply chains and sustainable healthcare systems.

The challenge facing Europe is therefore not whether it can innovate. It already does.

The real question is whether Europe can become the world’s most attractive place to discover, develop, manufacture and deploy biotechnology—and whether it can transform its scientific leadership into lasting industrial leadership.

The decisions taken during this legislative cycle may well determine Europe’s position in the global biotechnology landscape for decades to come. This is a window of opportunity that Europe cannot afford to miss.

This special edition of The European Files brings together European Commissioners, Members of the European Parliament, ministers, researchers, healthcare professionals, industry leaders and innovators to contribute to this essential debate. Together, they explore how Europe can seize the momentum created by the Biotech Act II to strengthen not only its health sovereignty, but also its competitiveness, strategic autonomy and global leadership.

Europe has the knowledge. Europe has the talent. Europe has the scientific excellence.

The next biotechnology revolution will not wait for Europe. The challenge now is to create the conditions for biotechnology to flourish—and remain—in Europe.

Editor-in-Chief 

Laurent ULMANN